Topics covered
- How to Prioritize Cost and Data Value: Evaluate up front which advanced immune monitoring technologies deliver useful data versus overwhelming volume especially with high-content platforms like flow and mIF.
- Choosing & Integrating Platforms: Strategic approaches to selecting and combining complementary and independent assay technologies for robust immune monitoring across sample types.
- Balancing Science, Operations, and Logistics: Practical guidance on experimental design and sample handling that maximizes data relevance while streamlining clinical operations.
- Avoiding Common Pitfalls: Key factors to avoid typical missteps in platform selection, assay planning, and biomarker strategy for impactful and effective early-phase studies.
Speakers
-
Rachel Owen, PhD
Rachel Owen, PhD is the vice president of immunology at Precision for Medicine. She is a global leader in immuno-oncology and infectious disease research, offering vast expertise in flow cytometry assay development, cell-based assays, and biomarker discovery. She is accustomed to both early and late phase clinical trials, making her a proficient strategist in translational studies. With her focus on providing valuable data for scientific discovery, she strengthens her partnerships in research.
(SizeLimitingPyList: [linkedin]) -
Deb Phippard, PhD
Deb Phippard, Chief Scientific Officer at Precision for Medicine. Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.
(SizeLimitingPyList: [linkedin])